Overview
Raltegravir is a potent, selective, and orally bioavailable inhibitor of HIV integrase (IC50 = 15 nM). It is metabolized primarily by uridine diphosphate glucuronosyltransferase 1A. Raltegravir has long-term efficacy and safety in managing HIV-1 infection in adults, children, and adolescents.
Application
Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Infection | HIV
Product Information
- Catalog No.: B2692-078687
- CAS No.: 871038-72-1
- Molecular Formula: C20H20FKN6O5
- Molecular Weight: 482.514
- Purity: 98%
- Storage: Powder : -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month
- Solubility: In Vitro : H2O: 25 mg/mL (51.81 mM; Need ultrasonic) DMSO : 6 mg/mL (12.43 mM; Need ultrasonic) In Vivo: 1.Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 0.6 mg/mL (1.24 mM); Clear solution 2.Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 0.6 mg/mL (1.24 mM); Clear solution 3.Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 0.6 mg/mL (1.24 mM); Clear solution
Source
Original product source